Clinical Trials Logo

Clinical Trial Summary

Aims: To compare clinical outcomes for patients under FLS and usual care at the NTUH MH and BB. Method: Four hundred subjects with new hip fracture or newly identified vertebral fracture are randomly assigned into FLS and usual care (UC). FLS subjects received osteoporosis-related assessments, treatments, consultations on diet, medications, exercise, fall preventions given mainly by care managers with followed up telephone call at 4, 8, 12, 18, 24 months then annually for up to 10 years. Care managers will perform baseline assessments and follow them by telephone annually for up to 10 years for UC subjects. Major outcomes include bone mineral density assessment rate, calcium, vitamin D, and osteoporosis medication initiation and adherence rate, fall and fracture incidences, mortality, and healthcare resource utilizations.


Clinical Trial Description

Background: First fragility fracture increased risk for further fracture for 2-4 folds. However, most fracture sufferers did not receive secondary prevention for osteoporosis to decrease future fracture risks. Since 2014, the National Taiwan University Hospital (NTUH) Healthcare system established fracture liaison services and were certified as gold (main hospital, MH) and silver (Beihu branch, BB) medal for best practices. Our preliminary results showed that compared with national average data, hip fracture patients under FLS may have lower mortality rate. However, randomized control trial (RCT) is still needed to confirm results from observational studies. Aims: to compare clinical outcomes for patients under FLS and usual care at the NTUH MH and BB. Method: Four hundred subjects with new hip fracture or newly identified vertebral fracture are randomly assigned into FLS and usual care (UC). FLS subjects received osteoporosis-related assessments, treatments, consultations on diet, medications, exercise, fall preventions given mainly by care managers with followed up telephone call at 4, 8, 12, 18, 24 months then annually for up to 10 years. Care managers will perform baseline assessments and follow them by telephone annually for up to 10 years for UC subjects. Major outcomes include bone mineral density assessment rate, calcium, vitamin D, and osteoporosis medication initiation and adherence rate, fall and fracture incidences, mortality, and healthcare resource utilizations. Anticipated results: Provide evidence on benefit of FLS in RCT on osteoporosis evaluation, medication initiation, mediation adherence, calcium, vitamin D, protein, exercise adherence, fall, re-fracture, mortality and other outcomes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03178799
Study type Observational
Source National Taiwan University Hospital
Contact
Status Enrolling by invitation
Phase
Start date June 23, 2017
Completion date December 31, 2028

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06024148 - Continuation of Anti-osteoporotic Treatment 1 Year After Initial Administration
Completed NCT03710889 - Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption Phase 3
Recruiting NCT05058976 - Romosozumab Use to Build Skeletal Integrity Phase 4
Completed NCT03798444 - Height Loss, Kyphosis Indicators, Bone Mineral Density and Vertebral Fractures in Chinese Postmenopausal Women
Completed NCT04960033 - Evaluating Fracture Risk Assessment Tools (FRAX) From Different Regions in Central South Chinese Postmenopausal Women
Not yet recruiting NCT04597931 - Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density Phase 4
Completed NCT05366621 - Post-fracture Medication and Mortality
Completed NCT02483286 - Osteoporosis and Fall Prevention With Multiple Interventions in the Metropolitan Area N/A
Completed NCT02803190 - Osteoporosis and Fall Prevention and Posture Correction Interventions in the Metropolitan Area N/A
Recruiting NCT03451305 - Postrual Reduction With Pillow in Osteoporotic Vertebral Fracture N/A
Recruiting NCT03811509 - Breast Cancer Women on Aromatase Inhibitors Treatment Phase 4
Recruiting NCT06379243 - Development and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures N/A